Phosphate Metabolism and Fibroblast Growth Factor 23 in Chronic Kidney Disease

Nutritional Management of Renal Disease

Volumn , Issue , 2013, Pages 285-308

  Houston, Jessica ^a   Isakova, Tamara ^a   Wolf, Myles ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883915127     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-391934-2.00020-5     Document Type: Chapter

References (175)

1. Phosphorus Krafft F. From elemental light to chemical element. Angew Chem Int Ed Engl 1969 Sep, 8(9):660-671.
2. USGS Minerals Information: Phosphate Rock. Phosphate Rock Statistics and Information 2011 [cited 19.08.11]. Available from: . http://minerals.usgs.gov/minerals/pubs/commodity/phosphate_rock/.
3. Boaz M., Smetana S. Regression equation predicts dietary phosphorus intake from estimate of dietary protein intake. J Am Diet Assoc. 1996 Dec, 96(12):1268-1270.
4. Noori N., Sims J.J., Kopple J.D., Shah A., Colman S., Shinaberger C.S., et al. Organic and inorganic dietary phosphorus and its management in chronic kidney disease. Iran J Kidney Dis 2010 Apr, 4(2):89-100.
5. Kalantar-Zadeh K., Gutekunst L., Mehrotra R., Kovesdy C.P., Bross R., Shinaberger C.S., et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010 Mar, 5(3):519-530.
6. Kutchal H. The Gastrointestinal System: Digestion and Absorption. Physiology 2004, 595-622. Elsevier, Philadelphia. 5th ed. R. Berne, M.N. Levy, B.M. Koeppen, B.A. Stanton (Eds.).
7. Moe S.M. Disorders Involving Calcium, Phosphorus, and Magnesium. Kidney Disease and Hypertension, Part I 2008, 215-238. Elsevier Inc. E. Lerma (Ed.).
8. Favus M., Bushinsky D.A., Lemann J. Regulation of Calcium, Magnesium, and Phosphate Metabolism. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 2006, 76-83. American Society for Bone and Mineral Research, Washington, DC. 6th ed. S. Christakos, M.F. Holick (Eds.).
9. Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment. Seminars in dialysis 2007 Jul-Aug, 20(4):286-294.
10. Isakova T., Gutierrez O., Shah A., Castaldo L., Holmes J., Lee H., et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008 Mar, 19(3):615-623.
11. Walling M.W. Intestinal Ca and phosphate transport: differential responses to vitamin D3 metabolites. Am J Physiol 1977 Dec, 233(6):E488-E494.
12. Radanovic T., Wagner C.A., Murer H., Biber J. Regulation of intestinal phosphate transport. I. Segmental expression and adaptation to low-P(i) diet of the type IIb Na(+)-P(i) cotransporter in mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2005 Mar, 288(3):G496-G500.
13. Stauber A., Radanovic T., Stange G., Murer H., Wagner C.A., Biber J. Regulation of intestinal phosphate transport. II. Metabolic acidosis stimulates Na(+)-dependent phosphate absorption and expression of the Na(+)-P(i) cotransporter NaPi-IIb in small intestine. Am J Physiol Gastrointest Liver Physiol 2005 Mar, 288(3):G501-G506.
14. Uribarri J. Phosphorus homeostasis in normal health and in chronic kidney disease patients with special emphasis on dietary phosphorus intake. Seminars in dialysis 2007 Jul-Aug, 20(4):295-301.
15. Liu S.H., Chu H.I. Studies on calcium and phosphorus metabolism with special reference to pathogenesis and effect of dihydrotachysterol (A.T. 10) and iron. Medicine 1943, 22:103-161.
16. Amanzadeh J., Reilly R.F. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2006 Mar, 2(3):136-148.
17. Marks J., Srai S.K., Biber J., Murer H., Unwin R.J., Debnam E.S. Intestinal phosphate absorption and the effect of vitamin D: a comparison of rats with mice. Exp Physiol 2006 May, 91(3):531-537.
18. Forster I.C., Virkki L., Bossi E., Murer H., Biber J. Electrogenic kinetics of a mammalian intestinal type IIb Na(+)/P(i) cotransporter. J Membr Biol. 2006, 212(3):177-190.
19. Villa-Bellosta R., Sorribas V. Role of rat sodium/phosphate cotransporters in the cell membrane transport of arsenate. Toxicol Appl Pharmacol 2008 Oct 1, 232(1):125-134.
20. Sabbagh Y., Giral H., Caldas Y., Levi M., Schiavi S.C. Intestinal phosphate transport. Adv Chronic Kidney Dis 2011 Mar, 18(2):85-90.
21. Xu H., Collins J.F., Bai L., Kiela P.R., Ghishan F.K. Regulation of the human sodium-phosphate cotransporter NaP(i)-IIb gene promoter by epidermal growth factor. Am J Physiol Cell Physiol 2001 Mar, 280(3):C628-C636.
22. Miyamoto K., Ito M., Kuwahata M., Kato S., Segawa H. Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 2005 Aug, 9(4):331-335.
23. Segawa H., Kaneko I., Yamanaka S., Ito M., Kuwahata M., Inoue Y., et al. Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. Am J Physiol Renal Physiol 2004 Jul, 287(1):F39-F47.
24. Marks J., Debnam E.S., Unwin R.J. Phosphate homeostasis and the renal-gastrointestinal axis. Am J Physiol Renal Physiol 2010 Aug, 299(2):F285-F296.
25. Katai K., Miyamoto K., Kishida S., Segawa H., Nii T., Tanaka H., et al. Regulation of intestinal Na+-dependent phosphate co-transporters by a low-phosphate diet and 1, 25-dihydroxyvitamin D3. Biochem J 1999 Nov 1, 343(Pt 3):705-712.
26. Gutierrez O.M., Wolf M. Dietary phosphorus restriction in advanced chronic kidney disease: merits, challenges, and emerging strategies. Seminars in dialysis 2010 Jul-Aug, 23(4):401-406.
27. Wolf M. Forging forward with 10 burning questions on FGF-23 in kidney disease. J Am Soc Nephrol 2010 Sep, 21(9):1427-1435.
28. Shimada T., Yoneya T., Hino R., Takeuchi Y., Fukumoto S., Yamashita T. Transgenic mice expressing FGF-23 demonstrate hypophosphatemia with low serum 1, 25-dihydroxyvitamin D and rickets/osteomalacia. J Bone Miner Res. 2001, 16. S151.
29. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren O., Tenenhouse H.S., et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004 Jul, 145(7):3087-3094.
30. Shimada T., Muto T., Urakawa I., Yoneya T., Yamazaki Y., Okawa K., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002 Aug, 143(8):3179-3182.
31. Saito H., Kusano K., Kinosaki M., Ito H., Hirata M., Segawa H., et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyvitamin D3 production. J Biol Chem. 2003 Jan 24, 278(4):2206-2211.
32. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004 Nov, 23(7):421-432.
33. Benet-Pages A., Orlik P., Strom T.M., Lorenz-Depiereux B. An FGF-23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005 Feb 1, 14(3):385-390.
34. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., et al. Klotho converts canonical FGF receptor into a specific receptor for FGF-23. Nature 2006 Dec 7, 444(7120):770-774.
35. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF-23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113(4):561-568.
36. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004, 19(3):429-435.
37. Kronenberg H.M. NPT2a - the key to phosphate homeostasis. N Engl J Med 2002 Sep 26, 347(13):1022-1024.
38. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., et al. The parathyroid is a target organ for FGF-23 in rats. J Clin Invest 2007 Dec, 117(12):4003-4008.
39. Burnett S.M., Gunawardene S.C., Bringhurst F.R., Juppner H., Lee H., Finkelstein J.S. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006 Aug, 21(8):1187-1196.
40. Ferrari S.L., Bonjour J.P., Rizzoli R. FGF-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2004 Dec 21.
41. Liu S., Tang W., Zhou J., Stubbs J.R., Luo Q., Pi M., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006 May, 17(5):1305-1315.
42. Lavi-Moshayoff V., Wasserman G., Meir T., Silver J., Naveh-Many T. PTH increases FGF-23 gene expression and mediates the high-FGF-23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010 Oct, 299(4):F882-F889.
43. Isakova T., Wahl P., Vargas G.S., Gutierrez O.M., Scialla J., Xie H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011 Jun, 79(12):1370-1378.
44. Craver L., Marco M.P., Martinez I., Rue M., Borras M., Martin M.L., et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 - achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007 Apr, 22(4):1171-1176.
45. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007 Jan, 71(1):31-38.
46. Gutierrez O., Isakova T., Rhee E., Shah A., Holmes J., Collerone G., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005 Jul, 16(7):2205-2215.
47. Hasegawa H., Nagano N., Urakawa I., Yamazaki Y., Iijima K., Fujita T., et al. Direct evidence for a causative role of FGF-23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010 Nov, 78(10):975-980.
48. Isakova T., Wolf M.S. FGF-23 or PTH: which comes first in CKD?. Kidney Int 2010 Nov, 78(10):947-949.
49. Pavik I., Jaeger P., Kistler A.D., Poster D., Krauer F., Cavelti-Weder C., et al. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int 2011 Jan, 79(2):234-240.
50. Pereira R.C., Juppner H., Azucena-Serrano C.E., Yadin O., Salusky I.B., Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009 Dec, 45(6):1161-1168.
51. Kuro-o M. Klotho in chronic kidney disease - what's new?. Nephrol Dial Transplant 2009 Jun, 24(6):1705-1708.
52. Samadfam R., Richard C., Nguyen-Yamamoto L., Bolivar I., Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 2009 Nov, 150(11):4835-4845.
53. Galitzer H., Ben-Dov I.Z., Silver J., Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010 Feb, 77(3):211-218.
54. Komaba H., Goto S., Fujii H., Hamada Y., Kobayashi A., Shibuya K., et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2010 Feb, 77(3):232-238.
55. Isakova T., Gutierrez O.M., Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 2009 Oct, 76(7):705-716.
56. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008 Aug 7, 359(6):584-592.
57. Isakova T., Xie H., Barchi-Chung A., Vargas G., Sowden N., Houston J., et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol 2011 Nov, 6(11):2688-2695.
58. Wesseling-Perry K., Pereira R.C., Sahney S., Gales B., Wang H.J., Elashoff R., et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011 Jan, 79(1):112-119.
59. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003 Dec, 64(6):2272-2279.
60. Shimada T., Urakawa I., Isakova T., Yamazaki Y., Epstein M., Wesseling-Perry K., et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010 Feb, 95(2):578-585.
61. Viaene L., Bammens B., Meijers B.K., Vanrenterghem Y., Vanderschueren D., Evenepoel P. Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. Nephrol Dial Transplant 2011 Oct 24.
62. Ambuhl P.M., Meier D., Wolf B., Dydak U., Boesiger P., Binswanger U. Metabolic aspects of phosphate replacement therapy for hypophosphatemia after renal transplantation: impact on muscular phosphate content, mineral metabolism, and acid/base homeostasis. Am J Kidney Dis 1999, 34(5):875-883.
63. Levi M. Post-transplant hypophosphatemia. Kidney Internat 2001, 59(6):2377-2387.
64. Felsenfeld A.J., Gutman R.A., Drezner M., Llach F. Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1, 25-dihydroxycholecalciferol. Mineral & Electrolyte Metab 1986, 12(5-6):333-341.
65. Parfitt A.M., Kleerekoper M., Cruz C. Reduced phosphate reabsorption unrelated to parathyroid hormone after renal transplantation: implications for the pathogenesis of hyperparathyroidism in chronic renal failure. Mineral & Electrolyte Metab 1986, 12(5-6):356-362.
66. Green J., Debby H., Lederer E., Levi M., Zajicek H.K., Bick T. Evidence for a PTH-independent humoral mechanism in post-transplant hypophosphatemia and phosphaturia. Kidney Internat 2001, 60(3):1182-1196.
67. Riancho J.A., de Francisco A.L., del Arco C., Amado J.A., Cotorruelo J.G., Arias M., et al. Serum levels of 1, 25-dihydroxyvitamin D after renal transplantation. Min Electrol Metabol 1988, 14(6):332-337.
68. Steiner R.W., Ziegler M., Halasz N.A., Catherwood B.D., Manolagas S., Deftos L.J. Effect of daily oral vitamin D and calcium therapy, hypophosphatemia, and endogenous 1-25 dihydroxycholecalciferol on parathyroid hormone and phosphate wasting in renal transplant recipients. Transplantation 1993, 56(4):843-846.
69. Seeherunvong W., Wolf M. Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. Pediatr Transplant 2011 Feb, 15(1):37-46.
70. Bhan I., Shah A., Holmes J., Isakova T., Gutierrez O., Burnett S.M., et al. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?. Kidney Int 2006 Oct, 70(8):1486-1494.
71. Sirilak S., Chatsrisak K., Ingsathit A., Kantachuvesiri S., Sumethkul V., Stitchantrakul W., et al. Renal phosphate loss in long-term kidney transplantation. Clin J Am Soc Nephrol 2012 Feb, 7(2):323-331.
72. Evenepoel P., Meijers B.K., de Jonge H., Naesens M., Bammens B., Claes K., et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol 2008 Nov, 3(6):1829-1836.
73. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 Sep 23, 351(13):1296-1305.
74. Landray M.J., Emberson J.R., Blackwell L., Dasgupta T., Zakeri R., Morgan M.D., et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 2010 Dec, 56(6):1082-1094.
75. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004 Aug, 15(8):2208-2218.
76. Kalantar-Zadeh K., Kuwae N., Regidor D.L., Kovesdy C.P., Kilpatrick R.D., Shinaberger C.S., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006 Aug, 70(4):771-780.
77. Kestenbaum B., Sampson J.N., Rudser K.D., Patterson D.J., Seliger S.L., Young B., et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005 Feb, 16(2):520-528.
78. Tonelli M., Sacks F., Pfeffer M., Gao Z., Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005 Oct 25, 112(17):2627-2633.
79. Strozecki P., Adamowicz A., Nartowicz E., Odrowaz-Sypniewska G., Wlodarczyk Z., Manitius J. Parathormon, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail. 2001 Jan, 23(1):115-126.
80. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000 May 18, 342(20):1478-1483.
81. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000 Sep 29, 87(7):E10-E17.
82. Blacher J., Guerin A.P., Pannier B., Marchais S.J., London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001 Oct, 38(4):938-942.
83. Cozzolino M., Brancaccio D., Gallieni M., Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005 Aug, 68(2):429-436.
84. Moe S.M., O'Neill K.D., Reslerova M., Fineberg N., Persohn S., Meyer C.A. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 2004 Sep, 19(9):2387-2393.
85. Adeney K.L., Siscovick D.S., Ix J.H., Seliger S.L., Shlipak M.G., Jenny N.S., et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2008 Dec 10.
86. Galetta F., Cupisti A., Franzoni F., Femia F.R., Rossi M., Barsotti G., et al. Left ventricular function and calcium phosphate plasma levels in uraemic patients. J Intern Med 2005 Oct, 258(4):378-384.
87. Culleton B.F., Walsh M., Klarenbach S.W., Mortis G., Scott-Douglas N., Quinn R.R., et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007 Sep 19, 298(11):1291-1299.
88. Isakova T., Gutierrez O.M., Chang Y., Shah A., Tamez H., Smith K., et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009 Feb, 20(2):388-396.
89. Kovesdy C.P., Kuchmak O., Lu J.L., Kalantar-Zadeh K. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD. Am J Kidney Dis 2010 Nov, 56(5):842-851.
90. Schwarz S., Trivedi B.K., Kalantar-Zadeh K., Kovesdy C.P. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 2006 Jul, 1(4):825-831.
91. Voormolen N., Noordzij M., Grootendorst D.C., Beetz I., Sijpkens Y.M., Manen J.G., et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007 Oct, 22(10):2909-2916.
92. Norris K.C., Greene T., Kopple J., Lea J., Lewis J., Lipkowitz M., et al. Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease. J Am Soc Nephrol 2006 Oct, 17(10):2928-2936.
93. Haut L.L., Alfrey A.C., Guggenheim S., Buddington B., Schrier N. Renal toxicity of phosphate in rats. Kidney Int 1980 Jun, 17(6):722-731.
94. Barsotti G., Giannoni A., Morelli E., Lazzeri M., Vlamis I., Baldi R., et al. The decline of renal function slowed by very low phosphorus intake in chronic renal patients following a low nitrogen diet. Clinical Nephrology 1984 Jan, 21(1):54-59.
95. Zoccali C., Ruggenenti P., Perna A., Leonardis D., Tripepi R., Tripepi G., et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol 2011 Oct, 22(10):1923-1930.
96. Cunningham J., Locatelli F., Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol 2011 Apr, 6(4):913-921.
97. Mak R.H., Turner C., Thompson T., Powell H., Haycock G.B., Chantler C. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. Br Med J (Clin Res Ed) 1985 Sep 7, 291(6496):623-627.
98. Portale A.A., Booth B.E., Halloran B.P., Morris R.C. Effect of dietary phosphorus on circulating concentrations of 1, 25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984 Jun, 73(6):1580-1589.
99. Markowitz M., Rotkin L., Rosen J.F. Circadian rhythms of blood minerals in humans. Science (New York, NY 1981 Aug 7, 213(4508):672-674.
100. Isakova T., Xie H., Yang W., Xie D., Anderson A.H., Scialla J., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011 Jun 15, 305(23):2432-2439.
101. Parker B.D., Schurgers L.J., Brandenburg V.M., Christenson R.H., Vermeer C., Ketteler M., et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010 May 18, 152(10):640-648.
102. Wolf M., Molnar M.Z., Amaral A.P., Czira M.E., Rudas A., Ujszaszi A., et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011 May, 22(5):956-966.
103. Kendrick J., Cheung A.K., Kaufman J.S., Greene T., Roberts W.L., Smits G., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011 Oct, 22(10):1913-1922.
104. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF-23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007 Sep, 18(9):2600-2608.
105. Titan S.M., Zatz R., Graciolli F.G., Dos Reis L.M., Barros R.T., Jorgetti V., et al. FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol 2011 Feb, 6(2):241-247.
106. Semba R.D., Fink J.C., Sun K., Cappola A.R., Dalal M., Crasto C., et al. Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol 2012 Jan, 7(1):85-91.
107. Seiler S., Reichart B., Roth D., Seibert E., Fliser D., Heine G.H. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010 Dec, 25(12):3983-3989.
108. Taylor E.N., Rimm E.B., Stampfer M.J., Curhan G.C. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 2011 May, 161(5):956-962.
109. Seiler S., Cremers B., Rebling N.M., Hornof F., Jeken J., Kersting S., et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J 2011 Nov, 32(21):2688-2696.
110. Ford M.L., Smith E.R., Tomlinson L.A., Chatterjee P.K., Rajkumar C., Holt S.G. FGF23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Nephrol Dial Transplant 2012 Feb, 27(2):727-733.
111. Hsu H.J., Wu M.S. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. The American Journal of the Medical Sciences 2009 Feb, 337(2):116-122.
112. Gutierrez O.M., Januzzi J.L., Isakova T., Laliberte K., Smith K., Collerone G., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009 May 19, 119(19):2545-2552.
113. Mirza M.A., Larsson A., Melhus H., Lind L., Larsson T.E. Serum intact FGF-23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009 Dec, 207(2):546-551.
114. Canziani M.E., Tomiyama C., Higa A., Draibe S.A., Carvalho A.B. Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif 2011, 31(1-3):26-32.
115. Kirkpantur A., Balci M., Gurbuz O.A., Afsar B., Canbakan B., Akdemir R., et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant 2011 Apr, 26(4):1346-1354.
116. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., et al. FGF-23 induces left ventricular hypertrophy. J Clin Invest 2011 Nov 1, 121(11):4393-4408.
117. Silberberg J.S., Barre P.E., Prichard S.S., Sniderman A.D. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 1989 Aug, 36(2):286-290.
118. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990 May 31, 322(22):1561-1566.
119. Roos M., Lutz J., Salmhofer H., Luppa P., Knauss A., Braun S., et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clinical Endocrinology 2008 Apr, 68(4):660-665.
120. Inaba M., Okuno S., Imanishi Y., Yamada S., Shioi A., Yamakawa T., et al. Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int 2006 Oct, 17(10):1506-1513.
121. Srivaths P.R., Goldstein S.L., Silverstein D.M., Krishnamurthy R., Brewer E.D., Elevated F.G.F. 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011 Jun, 26(6):945-951.
122. Mirza M.A., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009 Aug, 205(2):385-390.
123. Mirza M.A., Hansen T., Johansson L., Ahlstrom H., Larsson A., Lind L., et al. Relationship between circulating FGF-23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009 Oct, 24(10):3125-3131.
124. Desjardins L., Liabeuf S., Renard C., Lenglet A., Lemke H.D., Choukroun G., et al. FGF-23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012 Jul, 23(7):2017-2025.
125. Nakanishi S., Kazama J.J., Nii-Kono T., Omori K., Yamashita T., Fukumoto S., et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005 Mar, 67(3):1171-1178.
126. Kazama J.J., Sato F., Omori K., Hama H., Yamamoto S., Maruyama H., et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005 Mar, 67(3):1120-1125.
127. Sato T., Tominaga Y., Ueki T., Goto N., Matsuoka S., Katayama A., et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004 Sep, 44(3):481-487.
128. Wesseling-Perry K., Pereira R.C., Wang H., Elashoff R.M., Sahney S., Gales B., et al. Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009 Feb, 94(2):511-517.
129. Komaba H., Fukagawa M. FGF-23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 2010 Feb, 77(4):292-298.
130. Manghat P., Fraser W.D., Wierzbicki A.S., Fogelman I., Goldsmith D.J., Hampson G. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int 2010 Nov, 21(11):1853-1861.
131. Ashikaga E., Honda H., Suzuki H., Hosaka N., Hirai Y., Sanada D., et al. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial 2010 Jun, 14(3):315-322.
132. Chertow G.M., Levin N.W., Beck G.J., Depner T.A., Eggers P.W., Gassman J.J., et al. In-center hemodialysis six times per week versus three times per week. N Engl J Med 2010 Dec 9, 363(24):2287-2300.
133. Tonelli M., Pannu N., Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010 Apr 8, 362(14):1312-1324.
134. Sprague S.M., Abboud H., Qiu P., Dauphin M., Zhang P., Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009 Jan, 4(1):178-185.
135. Isakova T., Gutierrez O.M., Smith K., Epstein M., Keating L.K., Juppner H., et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011 Feb, 26(2):584-591.
136. Oliveira R.B., Cancela A.L., Graciolli F.G., Dos Reis L.M., Draibe S.A., Cuppari L., et al. Early control of PTH and FGF-23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol 2010 Feb, 5(2):286-291.
137. Gonzalez-Parra E., Gonzalez-Casaus M.L., Galan A., Martinez-Calero A., Navas V., Rodriguez M., et al. Lanthanum carbonate reduces FGF-23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011 Aug, 26(8):2567-2571.
138. Koiwa F., Kazama J.J., Tokumoto A., Onoda N., Kato H., Okada T., et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005 Aug, 9(4):336-339.
139. Nishi H., Nii-Kono T., Nakanishi S., Yamazaki Y., Yamashita T., Fukumoto S., et al. Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron 2005, 101(2):c94-c99.
140. Wetmore J.B., Liu S., Krebill R., Menard R., Quarles L.D. Effects of cinacalcet and concurrent low-dose vitamin D on FGF-23 levels in ESRD. Clin J Am Soc Nephrol 2010 Jan, 5(1):110-116.
141. Koizumi M., Komaba H., Nakanishi S., Fujimori A., Fukagawa M. Cinacalcet treatment and serum FGF-23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2011 Jul 5.
142. Block G.A., Martin K.J., de Francisco A.L., Turner S.A., Avram M.M., Suranyi M.G., et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004 Apr 8, 350(15):1516-1525.
143. Takeda Y., Komaba H., Goto S., Fujii H., Umezu M., Hasegawa H., et al. Effect of intravenous saccharated ferric oxide on serum FGF-23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011, 33(5):421-426.
144. Schouten B.J., Hunt P.J., Livesey J.H., Frampton C.M., Soule S.G. FGF-23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009 Jul, 94(7):2332-2337.
145. Farrow E.G., Yu X., Summers L.J., Davis S.I., Fleet J.C., Allen M.R., et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011 Nov 15, 108(46):E1146-E1155.
146. Imel E.A., Peacock M., Gray A.K., Padgett L.R., Hui S.L., Econs M.J. Iron modifies plasma FGF-23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011 Nov, 96(11):3541-3549.
147. Martin K.J., Bell G., Huang S., Pickthorn K., Kaskas M.O., Bernardo M., et al. The effect of KAI-4169, a novel treatment for chronic kidney disease-mineral and bone disorder, on serum phosphorus kinetics post-hemodialysis [Abstract]. J Am Soc Nephrol 2011, 22. 398A.
148. Schiavi S.C., Tang W., Bracken C., O'Brien S.P., Song W., Boulanger J., et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 2012 Oct, 23(10):1691-1700.
149. Uribarri J., Calvo M.S. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology?. Seminars in dialysis 2003 May-Jun, 16(3):186-188.
150. Karp H.J., Vaihia K.P., Karkkainen M.U., Niemisto M.J., Lamberg-Allardt C.J. Acute effects of different phosphorus sources on calcium and bone metabolism in young women: a whole-foods approach. Calcif Tissue Int 2007 Apr, 80(4):251-258.
151. Moe S.M., Chen N.X., Seifert M.F., Sinders R.M., Duan D., Chen X., et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 2009 Jan, 75(2):176-184.
152. Taylor L.M., Kalantar-Zadeh K., Markewich T., Colman S., Benner D., Sim J.J., et al. Dietary egg whites for phosphorus control in maintenance haemodialysis patients: a pilot study. J Ren Care 2011 Mar, 37(1):16-24.
153. Iqbal T.H., Lewis K.O., Cooper B.T. Phytase activity in the human and rat small intestine. Gut 1994 Sep, 35(9):1233-1236.
154. Food Ingredient and Color: International Food Information Council (IFIC) and U.S. Food and Drug Administration. Types of Food Ingredients 2010 [cited 2011 December 7]. Available from: . http://www.fda.gov/food/foodingredientspackaging/ucm094211.htm%23types.
155. Sullivan C., Sayre S.S., Leon J.B., Machekano R., Love T.E., Porter D., et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 2009 Feb 11, 301(6):629-635.
156. Moe S.M., Zidehsarai M.P., Chambers M.A., Jackman L.A., Radcliffe J.S., Trevino L.L., et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011 Feb, 6(2):257-264.
157. Ludwig D.S. Technology, diet, and the burden of chronic disease. JAMA 2011 Apr 6, 305(13):1352-1353.
158. Sullivan C.M., Leon J.B., Sehgal A.R. Phosphorus-containing food additives and the accuracy of nutrient databases: implications for renal patients. J Ren Nutr 2007 Sep, 17(5):350-354.
159. Sherman R.A., Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin J Am Soc Nephrol 2009 Aug, 4(8):1370-1373.
160. Oenning L.L., Vogel J., Calvo M.S. Accuracy of methods estimating calcium and phosphorus intake in daily diets. J Am Diet Assoc 1988 Sep, 88(9):1076-1080.
161. Karalis M., Murphy-Gutekunst L. Patient education. Enhanced foods: hidden phosphorus and sodium in foods commonly eaten. J Ren Nutr 2006 Jan, 16(1):79-81.
162. Shinaberger C.S., Greenland S., Kopple J.D., Van Wyck D., Mehrotra R., Kovesdy C.P., et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?. Am J Clin Nutr 2008 Dec, 88(6):1511-1518.
163. Bohn T., Davidsson L., Walczyk T., Hurrell R.F. Phytic acid added to white-wheat bread inhibits fractional apparent magnesium absorption in humans. Am J Clin Nutr 2004 Mar, 79(3):418-423.
164. Hallberg L., Rossander L., Skanberg A.B. Phytates and the inhibitory effect of bran on iron absorption in man. Am J Clin Nutr 1987 May, 45(5):988-996.
165. Turnlund J.R., King J.C., Keyes W.R., Gong B., Michel M.C. A stable isotope study of zinc absorption in young men: effects of phytate and alpha-cellulose. Am J Clin Nutr 1984 Nov, 40(5):1071-1077.
166. Spencer H., Kramer L., Norris C., Osis D. Effect of calcium and phosphorus on zinc metabolism in man. Am J Clin Nutr 1984 Dec, 40(6):1213-1218.
167. Schiller L.R., Santa Ana C.A., Sheikh M.S., Emmett M., Fordtran J.S. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989 Apr 27, 320(17):1110-1113.
168. Litzow J.R., Lemann J., Lennon E.J. The effect of treatment of acidosis on calcium balance in patients with chronic azotemic renal disease. J Clin Invest 1967 Feb, 46(2):280-286.
169. Hill K.M., Martin B., Moe S.M., McCabe G.P., Weaver C.M., Peacock M. Effect of calcium carbonate supplement on phosphate balance and homeostasis in patients with stage 3 and 4 chronic kidney Disease [Abstract]. J Am Soc Nephrol 2011, 22. 4A.
170. Moe S.M., Radcliffe J.S., White K.E., Gattone V.H., Seifert M.F., Chen X., et al. The pathophysiology of early stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. J Bone Miner Res 2011 Nov, 26(11):2672-2681.
171. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003 Jul 31, 349(5):446-456.
172. Shoben A.B., Rudser K.D., de Boer I.H., Young B., Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008 Aug, 19(8):1613-1619.
173. Teng M., Wolf M., Ofsthun M.N., Lazarus J.M., Hernan M.A., Camargo C.A., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005 Apr, 16(4):1115-1125.
174. Holick M.F. Vitamin D deficiency. N Engl J Med 2007 Jul 19, 357(3):266-281.
175. Murphy-Gutekunst L., Uribarri J. Hidden Phosphorus-Enhanced Meats: Part 3. J Ren Nutr 2005, 15(4):E1-E4.